Low-Grade Serous Ovarian Cancer: A Comprehensive Guide
"Understanding, managing, and living with this rare ovarian cancer subtype"
Ovarian cancer ranks as the second most lethal gynecological malignancy, demanding increased awareness and targeted strategies. While various types exist, this article focuses on low-grade serous ovarian carcinoma (LGSOC), a distinct subtype requiring specialized care. The World Health Organization classifies ovarian cancers into epithelial, non-epithelial, and metastatic types. Among these, serous ovarian carcinoma is further divided into high-grade serous (HGSOC) and low-grade serous ovarian carcinoma (LGSOC).
The distinction between HGSOC and LGSOC is critical. In 2004, a two-tier system based on nuclear atypia was introduced, leading to the recognition of LGSOC as a separate entity with unique genetic and clinical characteristics. LGSOC accounts for only 5-10% of serous ovarian carcinomas, presenting unique challenges in research and treatment due to its relative rarity.
This article aims to provide a comprehensive overview of LGSOC, translating complex research into accessible information for patients, families, and healthcare professionals. We will explore the diagnosis, treatment, and management of LGSOC, highlighting the latest findings and strategies for improving outcomes.
How Common LGSOC Is
Low-grade serous ovarian cancer (LGSOC) is a rare epithelial ovarian cancer that is less frequent than high-grade serous carcinoma and tends to affect younger women. The LGSOC Initiative estimates that 2–5 out of every 100 people diagnosed with ovarian cancer have LGSOC, and estimates that 65,000–160,000 women worldwide are living with it. The expert consensus report notes that many affected women endure years of ineffective treatment and poor quality of life.
Distinct Disease, Limited Chemotherapy Sensitivity
LGSOC has different pathological, epidemiological, and clinical features from high-grade serous ovarian cancer and is considered a distinct subtype. The expert consensus report says it is poorly sensitive to chemotherapy, while noting that the disease’s pathogenesis and management remain incompletely understood. A 2025 treatment-strategies review likewise describes limited sensitivity to conventional chemotherapy and calls for alternative treatment approaches.
Navigating LGSOC: Diagnosis, Treatment, and Management
Diagnosing LGSOC typically involves a combination of clinical evaluation, imaging, and histological assessment. Patients often present with symptoms similar to other ovarian cancers, such as abdominal or pelvic pain, bloating, or bowel dysfunction. Diagnostic workup includes a pelvic exam, CA125 blood test, and imaging studies like ultrasound or CT scans. LGSOC can arise de novo or from a serous borderline tumor (sBOT).
- Surgery: Aim for complete resection during primary cytoreductive surgery. If complete resection isn't possible initially, neoadjuvant chemotherapy followed by interval debulking surgery may be considered. Microscopic residual disease after surgery leads to better overall survival.
- Chemotherapy: Adjuvant chemotherapy is generally recommended, though LGSOC is less chemo-sensitive than HGSOC. For advanced cases, regimens containing carboplatin and paclitaxel are used.
- Hormonal Therapy: LGSOC often expresses estrogen and progesterone receptors, making hormonal therapy a viable option. Studies suggest hormonal maintenance therapy after chemotherapy improves progression-free survival.
- Targeted Therapies: Given the prevalence of KRAS/BRAF/MAPK pathway mutations, targeted agents are being investigated. MEK inhibitors have shown promise in clinical trials.
A Prognostic Comparison in the Literature
The cited observational retrospective study on LGSOC reports a comparison point from the Gynecologic Oncology Group (GOG) 218 study: median overall survival for women with stage III and IV high-grade serous ovarian cancer was reported as 39 months. The supplied excerpt gives this figure as background from GOG 218; it does not provide an LGSOC survival estimate or a direct comparison of outcomes.
Evidence and Treatment Challenges
Because less than 10% of ovarian serous carcinomas are low-grade, patients with LGSOC make up only a small number of participants in ovarian cancer clinical trials. A retrospective MD Anderson Cancer Centre study of 41 patients with recurrent disease found that cytoreduction without macroscopic residual disease was achieved in only 22% of patients. A 2025 review also characterizes LGSOC as having limited sensitivity to conventional chemotherapy and a distinct molecular landscape that creates a need for alternative treatment approaches.
Hope and the Future of LGSOC Treatment
Low-grade serous carcinoma presents unique challenges due to its rarity and relative chemo-resistance. However, surgery remains a critical component of treatment, both in the initial stages and for recurrence. The integration of hormonal therapy and targeted agents offers new avenues for improving patient outcomes.
What the Expert Consensus Covers
The 2023 expert consensus report was written for a medical audience and addresses diagnosis, risk factors, biomarkers, imaging, genetic testing, treatment, and monitoring of low-grade serous cancer. Its scope brings together multiple areas of clinical practice and disease research in one resource.
Research and Trial Developments
A guide published September 18, 2025, highlights LGSOC research, promising clinical trials, and new treatment options, reflecting continued investigation into care. In a separate report dated April 14, 2026, results from the NRG-GY019 trial presented at the 2026 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer showed that letrozole monotherapy failed to demonstrate noninferiority to chemotherapy followed by letrozole in patients with stage II–IV LGSOC. These findings identify an ongoing research direction while reporting a specific trial comparison.
Ongoing research and clinical trials are crucial for developing more effective treatments for LGSOC. Investigating targeted therapies that address specific mutations in the KRAS/BRAF/MAPK and PI3K/AKT/mTOR pathways holds significant promise. Continued efforts to understand the molecular underpinnings of LGSOC will pave the way for personalized treatment strategies.
Living with LGSOC requires a collaborative approach between patients, families, and healthcare providers. Accessing support networks, participating in clinical trials, and staying informed about the latest research are essential. While LGSOC presents challenges, ongoing advances offer hope for improved outcomes and enhanced quality of life.